No Data
Press Release: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Se
Express News | Travere Therapeutics Inc : BofA Global Research Cuts Price Objective to $19 From $21
Travere Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Travere Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
In the last three months, 6 analysts have published ratings on Travere Therapeutics (NASDAQ:TVTX), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their rec
Express News | Travere Therapeutics Shares Are Trading Higher Following Q1 Earnings